metronidazole and azithromycin — Competitive Intelligence Brief

metronidazole and azithromycin (metronidazole and azithromycin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antibiotic combination. Area: Infectious Disease.

marketed Antibiotic combination Bacterial DNA (metronidazole); bacterial 50S ribosome (azithromycin) Infectious Disease Small molecule

Target snapshot

metronidazole and azithromycin (metronidazole and azithromycin) — University of Alabama at Birmingham. This combination uses metronidazole to disrupt bacterial DNA and azithromycin to inhibit bacterial protein synthesis, together targeting anaerobic and aerobic pathogens.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
metronidazole and azithromycin TARGET	metronidazole and azithromycin	University of Alabama at Birmingham	marketed	Antibiotic combination	Bacterial DNA (metronidazole); bacterial 50S ribosome (azithromycin)
Intranasal Mupirocin and Topical Chlorhexidine	Intranasal Mupirocin and Topical Chlorhexidine	University of Maryland, Baltimore	marketed	Topical antibiotic combination	Bacterial isoleucyl-tRNA synthetase (mupirocin); bacterial cell membrane and proteins (chlorhexidine)
Omeprazole, Amoxicillin, Metronidazole and Clarithromycin	Omeprazole, Amoxicillin, Metronidazole and Clarithromycin	Al-Azhar University	marketed	Proton pump inhibitor + antibiotic combination therapy	H+ ATPase (omeprazole); bacterial ribosome and cell wall (amoxicillin, clarithromycin); bacterial DNA (metronidazole)
Lansoprazole/Amoxicillin/Clarithromycin	Lansoprazole/Amoxicillin/Clarithromycin	HK inno.N Corporation	marketed	Proton pump inhibitor + antibiotic combination	H+ ATPase (lansoprazole); bacterial cell wall (amoxicillin); bacterial ribosome (clarithromycin)
clindamycin 1% / benzoyl peroxide 5% tube	clindamycin 1% / benzoyl peroxide 5% tube	Sanofi	marketed	Topical antibiotic combination	Bacterial 50S ribosome (clindamycin); reactive oxygen species generation (benzoyl peroxide)
Dexamethasone+Tobramycin eye drop	Dexamethasone+Tobramycin eye drop	Azienda USL Reggio Emilia - IRCCS	marketed	Corticosteroid + aminoglycoside antibiotic combination	Glucocorticoid receptor (dexamethasone); bacterial 30S ribosome (tobramycin)
ceftriaxone/oxacillin	ceftriaxone/oxacillin	UPECLIN HC FM Botucatu Unesp	marketed	Beta-lactam antibiotic combination	Penicillin-binding proteins (PBPs)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antibiotic combination class)

1. Michael E. DeBakey VA Medical Center · 2 drugs in this class
2. University of South Florida · 2 drugs in this class
3. Halmstad County Hospital · 1 drug in this class
4. Hospital General Universitario Elche · 1 drug in this class
5. Hospital de Clinicas de Porto Alegre · 1 drug in this class
6. McMaster University · 1 drug in this class
7. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
8. Shanghai Jiao Tong University School of Medicine · 1 drug in this class
9. The Cleveland Clinic · 1 drug in this class
10. The Forsyth Institute · 1 drug in this class